RSV: The Disease and Pipeline Vaccines

Originally published by Informed Choice WA

UPDATED August 27, 2023

Several highly concerning RSV products have now been licensed and approved for use in our most vulnerable populations: pregnant women, newborns and those age 60 and over.

Prepare to be bombarded by marketing messages and pressure from doctors and nurses, who will be unaware of the concerns raised in the clinical trials, the lack of longterm safety studies, or the potential for unintended consequences of the use of the products. Educate yourself on the history of the transitory infection, the factors that increase susceptibility to severe disease, the nutrient and natural prevention and treatment options, naturally acquired immunity, and passive immunity from mother to child.

If you don’t already have a trusted health care provider aligned with your approach to health and wellness, interview health care providers until you find one to serve your needs.

Resources for learning more about the products and RSV treatment information below.

PREGNANT WOMEN

The U.S. Food and Drug Administration on Monday approved Pfizer’s Abrysvo vaccine, a maternal vaccine meant to protect infants against respiratory syncytial virus, or RSV, through 6 months of age — despite safety concerns, including from the FDA’s own advisers. READ FULL ARTICLE

Listen to medical student at Mount Sinai calmly and methodically deconstruct the safety/efficacy analyses for the RSV vaccine for pregnant women. https://t.co/DwyitEjKJW

— Aaron Siri (@AaronSiriSG) May 21, 2023

NEWBORNS

DEFENDER ARTICLE:

Despite 12 Deaths During Clinical Trials, CDC Signs Off on RSV Shots for Newborns by Michael Nevradakis, Ph.D.

Medical experts criticized the Centers for Disease Control and Prevention’s Thursday decision to recommend a “new immunization” for newborns to protect against respiratory syncytial virus, or RSV, calling the move unnecessary and not worth the known risks. READ FULL DEFENDER ARTICLE

FDA Press Release on AstraZeneca’s BEYFORTUS

FDA product insert for BEYFORTUS

AGED 60+

HISTORY of RSV

From NVIC.ORG:

What is the History of Respiratory Syncytial Virus (RSV) infection in the U.S. and other countries?
“Respiratory Syncytial Virus (RSV) was initially identified in 1955 by JA Morris in laboratory chimpanzees housed at Walter Reed Army Institute of Research in Maryland. The chimpanzees, which were used in polio vaccine research, exhibited symptoms of respiratory illness. Morris was able to confirm that the viral agent, which was initially named Chimpanzee Coryza Agent (CCA), was contagious when he exposed a second group of chimpanzees to the infection” . . . READ MORE.

• • What is RSV?
  • Is RSV Contagious?
  • What is the History of RSV in the U.S. and other countries?
  • Can RSV cause injury or death?
  • Who is Most at Risk for RSV?
  • Who is Most at Risk of Complications from Respiratory Syncytial Virus (RSV)?
  • Can RSV be Prevented and are there Treatment Options?
  • Quick facts
  • View all Respiratory Syncytial Virus (RSV) topic sections

From The Defender: 08/27/21 From Chimpanzees to Children: The Origins of RSV — Respiratory Syncytial Virus

TREATMENT

From the FLCCC Alliance: